Congenital fibrinogen deficiency market forecast to reach $800m across 3MM by 2031
Pharmaceutical Technology
DECEMBER 15, 2022
Therefore, there is also a significant need for new therapies that target the underlying cause of CFD that may offer a cure for patients living with severe disease, or for patients with genotypes such as dysfibrinogenemia and hypodysfibrinogenemia, who are often ineligible for treatment with HFCs.
Let's personalize your content